ArticleDiscover oncology2025
CYBB as a potential therapeutic target through influencing ferroptosis and macrophage in ovarian cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- TAMs in the Gynecological Tumor Microenvironment: Insights from Cross-Cancer Studies for Immunotherapy.Cancers · 2026Review
- Advances in ferroptosis research in ovarian cancer: molecular mechanisms and therapeutic perspectives.American journal of cancer research · 2026Review
- Deciphering the macrophage ferroptosis regulatory network: construction of an ulcerative colitis diagnostic model and investigation of the immune microenvironment based on single-cell and transcriptomic data.Frontiers in immunology · 2026Article
- Macrophages and neutrophils in ovarian cancer microenvironment.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionThe synergistic function between ferroptosis and tumor-associated macrophages (TAMs) has gained significant attention, but their relationship remains unclear. This study explores their roles and mechanisms in ovarian cancer progression, offering insights for potential therapeutic targets.
methodsFrom public databases, 4410 immune-related ovarian genes and 483 ferroptosis-related genes were collected. Using bioinformatics analysis, CYBB was identified as a key gene strongly associated with macrophage infiltration and ferroptosis. The immune infiltration of CYBB in ovarian cancer was evaluated using TIMER2, TISIDB, linkedOmics, GEPIA2, and TISCH databases. The expression and function of CYBB in ovarian cancer were further validated through in vitro cellular assays. Through establishing an in vitro TAMs co-culture model, we investigated the role of CYBB in modulating macrophage polarization.
resultsOur findings revealed that CYBB is highly expressed in ovarian cancer and associated with poor prognosis. Single-cell sequencing indicated that CYBB is predominantly expressed in macrophages, and enrichment analysis demonstrated that genes co-expressed with CYBB are primarily involved in macrophage activation. Through in vitro experiments, we found that CYBB influences ovarian cancer cell proliferation and erastin-induced ferroptosis. In TAMs, CYBB knockdown increased ferroptosis-related proteins (FTH-1,FSP1). Notably, CYBB knockout suppressed the expression of M1 macrophage markers while promoting the upregulation of M2 marker expression.
conclusionCYBB has prognostic and clinical significance in Ovarian cancer, playing a key role in the immune microenvironment by regulating macrophage infiltration and ferroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.